Archive for September 19th, 2011

Clinical trial updates for KERX INHX AEN

Sep 19, 2011 No Comments by

Inhibitex, Inc. (Nasdaq: INHX), announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients. Keryx Biopharmaceuticals (Nasdaq: KERX) […]

Daily News Read more